1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine Dihydrochloride CAS 1628047-87-9

Product Description:

Product Name:

1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride CAS NO: 1628047-87-9

Synonyms:

1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]piperazine dihydrochloride;

ABT199 intermediate 1;

1-((4-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride;

Chemical & Physical Properties:

Appearance: Light beige crystals

Assay :≥99.00%

Exact Mass: 390.139618

Long-Term Storage: Store long-term in a cool, dry place

Safety Information:

Signal Word: Warning     

Precautionary Statements: P261-P305+P351+P338

Hazard Statements: H302-H315-H319-H335

ABT-199 is a new cancer drug developed by the International Group for Research on Cancer (IARC) that has the potential to be used against cancer with fewer side effects and faster efficacy than existing drugs available for cancer treatment. ABT-199 is a new class of drugs that, unlike Chemicalbook, attack an important protein called Bcl-2 to treat cancer. Intermediate 1 of ABT199 is an intermediate in the synthesis of ABT199. Intermediate 1 (ABT199) is a precursor of ABT199 for the synthesis of anti-cancer drugs and can be used as a pharmaceutical intermediate. 4-((2-(4-chlorophenyl)-4, 4-dimethyl-1-cyclohexene) methyl) piperazine dihydrochloride is an intermediate used in the preparation of Venetoclax, which is a potent selective Chemicalbook selective inhibitor of Bcl-2 with strong antitumor activity while preserving platelets. Venetoclax is used to treat chronic lymphoblastic leukemia cells and e-strogen receptor-positive breast cancer.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.